Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

NCT01419691 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma
Leukemia, Prolymphocytic

Interventions

DRUG: auranofin

Sponsor

University of Kansas Medical Center

Collaborators

[object Object]
[object Object]
[object Object]